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by flow cytometryIn vitro differentiation of human pluripotent stem cells (hPSCs) offers a genetically tractable
system to examine the physiology and pathology of human tissue development and
differentiation. We have used this approach to model the earliest stages of human B lineage
development and characterize potential target cells for the in utero initiation of childhood B
acute lymphoblastic leukemia. Herein, we detail critical aspects of the protocol including reagent
validation, controls, and examples of surface markers used for analysis and cell sorting.Richardson et al., STAR
Protocols 2, 100420
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https://doi.org/10.1016/j.xpro.2021.100420SUMMARY
In vitro differentiation of human pluripotent stem cells (hPSCs) offers a geneti-
cally tractable system to examine the physiology and pathology of human tissue
development and differentiation. We have used this approach to model the
earliest stages of human B lineage development and characterize potential
target cells for the in utero initiation of childhood B acute lymphoblastic leuke-
mia. Herein, we detail critical aspects of the protocol including reagent valida-
tion, controls, and examples of surface markers used for analysis and cell sorting.
For complete details on the use and execution of this protocol, please refer to
Boiers et al. (2018).BEFORE YOU BEGIN
Establish feeder-free hPSC culture
Timing: 1–2 weeks
1. Identify a suitable hPSC line.
Note: It is widely considered that different hPSC lines can exhibit lineage biases upon differ-
entiation, which raises the possibility that certain cell lines will exhibit limited or no B lineage
differentiation potential. When establishing this protocol, we therefore strongly advise vali-
dating the system using a well-maintained hPSC line with known B lineage potential. We
have demonstrated robust B lineage output from the widely available H1 human embryonic
stem (ES) cells and ShIPS-MIFF3 (and to a lesser extent MIFF1) human induced pluripotent
stem cell (iPSC) lines.
2. Prepare Matrigel-coated 6 well plates.
a. Thaw stock vial of Matrigel on ice at 4C for 8–12 h.
b. Aliquot working stocks into chilled 15 mL conical tubes, using chilled tips on ice according to
the dilution factor supplied by the manufacturer and store at 20C.STAR Protocols 2, 100420, June 18, 2021 ª 2021 The Author(s).





Protocolc. Thaw Matrigel aliquots on ice and resuspend in an appropriate volume of chilled DMEM/F12
basal media using a chilled serological pipette. Dispense 1 mL of 13 Matrigel per well of a 6
well plate to coat the base. These plates can be stored at 4C for up to 7 days and used after
1 h of warming at 37C.
d. Remove Matrigel immediately prior to use; do not allow plates to desiccate.
CRITICAL: Matrigel must be handled at ice cold temperatures until applied to the surfaceto be coated. See manufacturer’s instructions for more details.3. Prepare StemFit (Basic04) hPSC media
a. Thaw the media at 4C for 8–12 h.
b. Aliquot in 50 mL or 15 mL conical tubes and store at 20C.
c. Thaw before use and add 10 ng/mL human basic Fibroblast Growth Factor (hbFGF).
Note:Avoid prolonged incubation at 37C as this degrades hbFGF. StemFit media is not used
beyond 7 days of storage at 4C. Higher concentrations of hbFGF may be needed.
Optional: 1% Penicillin/Streptomycin can be added to the media.
Alternative:We have also successfully used hPSCs grown in mTeSR1/mTeSR Plus media in this
protocol, used according to manufacturer’s instructions.
4. Prepare 10003 solution of Y27632 (ROCK inhibitor).
a. Reconstitute Y27632 powder in distilled water to a final concentration of 10 mM, aliquot into
sterile tubes and store at 20C.
b. Add 1:1000 of stock Y27632 to StemFit media to create a final concentration of 10mM. Work-
ing aliquots can be stored at 4C for up to 72 h and should not be freeze-thawed.
Note: Y27632 (ROCK inhibitor) containing media should be replaced with fresh basal media
after 24 h as it affects hPSC colony morphology, however, we sometimes extend to 48h where
hPSC viability is particularly compromised (e.g., difficult thawing or single cell cloning).
Note: hPSC lines tolerate single cell dissociation poorly. We therefore recommend adding
Y27632 to the hPSC media during thawing, routine passage, and single cell manipulations
(e.g., flow cytometry, cloning by limiting dilution etc.).
5. Thaw hPSC line(s).
a. Prepare an appropriate aliquot of Y27632-containing StemFit media as above.
b. Rapidly thaw a cryovial of hPSCs in a 37C water bath. Transfer cells to a 15 mL conical tube,
ensuring minimal break up of cell clumps.
c. Slowly dilute freezing media with the addition of 103 excess volume of fresh, warm StemFit.
d. Centrifuge for 5 min at 200 g.
e. Remove Matrigel from 6 well plate and replace with 1.5 mL Y27632-containing StemFit.
f. Remove the supernatant and gently resuspend the cell pellet in 1 mL Y27632-containing
StemFit. Transfer to a well of a 6 well plate in a final volume of 2.5 mL StemFit.
g. Feed daily with fresh media, avoiding exposure to more than 24 h (max 48 h if concerns
regarding viability) Y27632.
Note: Cells grown in StemFit Basic04 media have regular complete media changes, but do
not require daily feeding. See manufacturer’s instructions for recommended passaging/
feeding schedules (https://www.nippongenetics.eu/en/product/stemfit-basic04/).
Note:We routinely freeze hPSCs in 90% Knock Out Serum Replacement (KOSR)/10% DMSO.STAR Protocols 2, 100420, June 18, 2021
Figure 1. Morphology of hPSCs
(A) Photo of an undifferentiated MIFF3 IPS clone on Matrigel and in StemFit media.
(B) Photo of an undifferentiated MIFF3 IPS clone on Matrigel and in StemFit media just before passage.
(C) Differentiated MIFF3 hIPS colony unsuitable for use in differentiation.
Microscope Olympus, CKX53. Scale bars were added using ImageJ software.
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OPEN ACCESSProtocol6. Routine passage of hPSCs.
a. hPSCs are passaged when colonies are large or showing signs of differentiation. In general,
well-maintained colonies that are fed regularly and passaged in a timely way do not require
manual or chemical removal of differentiated cells (Figures 1A–1C).
b. Remove StemFit media and replace with 1 mL gentle cell dissociation reagent (GCDR).
c. Incubate at 37C for 5min.
Note: The time required in GCDR varies depending on the hPSC line used.
d. Gently remove GCDR avoiding disturbing the colonies and replace with 1 mL Y27632-contain-
ing StemFit media.
e. Mechanically scrape hPSC colonies using a cell scraper into clumps. If there are large visible
clumps, gently titurate the cell suspension with a 1 mL pipette tip and transfer to a new Matri-
gel-coated 6 well plate at an appropriate cell density.
Alternative: For passaging hPSCs, GCDR can be replaced with ReLeSr, which preferentially
detaches undifferentiated hPSC cells.
Note: Centrifugation during passage is not necessary and cells can be split directly into a new
plate. The precise seeding density depends on the characteristics of the hPSC line being used;
in our hands a 1:4 to 1:10 split would be routine for H1 hES or MIFF3 hIPS cells.
Note: In our experience hPSCs are not sufficiently established for B cell differentiation for at
least 2 passages (about 10 days) after thawing.Maintenance and storage of differentiation-competent OP9 and MS5 stroma
Timing: 2 weeks
CRITICAL: The quality of OP9 stroma used is one of themost important aspects of this pro-tocol. OP9 during maintenance should not be allowed to overgrow and are splitSTAR Protocols 2, 100420, June 18, 2021 3
Figure 2. Morphology of OP9 stroma in maintenance phase
(A) Sparse OP9 cells in maintenance.
(B) OP9 prior to passage at 80% confluency.
Microscope Olympus, CKX53. Scale bars were added using ImageJ software.
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OPEN ACCESS Protocolapproximately every 4 days to maintain a morphological profile shown in Figure 2A and 2B.
Failure tomaintain good quality OP9 will result in morphological changes such as increased
adiposity and an associated reduction or failure to generate hematopoietic progenitors.CRITICAL: The choice of plastic used in the tissue culture plate can affect differentiation(see Key Resources Table).7. Reserve batch of qualified FBS.
CRITICAL: It is important to use qualified FBS and different batches can affect both themorphology of OP9 and the yield of B cells. We therefore recommend reserving batches
of qualified FBS and testing for adequate B lineage output prior to committing to purchase.Note: FBS used in this protocol does not require heat inactivation.
8. Make OP9 maintenance (OP9-M) media as per instructions below.
CRITICAL: We have found that the use of aMEM made from powder is essential.
9. Expand stocks of OP9 stroma.
a. Pre-gelatinize 10 cm tissue culture dish with 5 mL 0.1% bovine gelatin for at least 12 h at 4C.4
CRITICAL: The use of pre-gelatinized plates is essential to maintain good stromalmorphology and integrity during differentiation. We routinely gelatinize plates for 1–
4 days at 4C prior to passage.b. Thaw cryovial of OP9 in 103 volume of OP9-M media, transfer to 15 mL conical tube and
centrifuge at 300 g for 5min.
c. Completely remove gelatin from 10 cm plate and seed OP9 cell pellet in 10 mL OP9-Mmedia.
d. Monitor daily for growth and passage tomaintain morphology as per Figures 2A and 2B. Once
established routine passage is typically a 1:4 split every 4 days.
Note: Early passage OP9 may grow faster, requiring passaging more frequently than 4 days.
Do not allow OP9 maintenance cultures to overgrow.
e. When passaging, remove and discard all media, wash twice gently with 5 mL DPBS to remove
all remaining media (this will help to maximize the effect of trypsin).
f. Add 5 mL freshly thawed trypsin (0.05% in DPBS, 5 mM EDTA).
g. Incubate for 5min at 37C.STAR Protocols 2, 100420, June 18, 2021
Figure 3. Morphology of MS5 stroma in maintenance phase
(A) MS5 stromal morphology prior to passage.
(B) MS5 stromal morphology when overgrown; do not use in further experiments.
Microscope Olympus, CKX53. Scale bars were added using ImageJ software.
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OPEN ACCESSProtocolNote: Further incubation up to a total of 7min may be required. If the stroma is not starting to
dissociate after this, gently titurate in the trypsin using a 5 mL serological pipette.
h. Quench trypsin with 5 mL OP9-Mmedia, titurate cells until stromal layer is uniformly detached
and transfer to a 15 mL conical tube.
i. Centrifuge at 300 g for 5min.
j. Count cells and plate 70 000 – 100 000 cells into 10 mL OP9-M media into new, gelatinized
10 cm tissue culture dish (typically 1:4 split).
CRITICAL: As the stroma is routinely grown to near confluence effective dissociation isessential. We recommend using trypsin from freshly thawed aliquots and meticulously
washing the stroma of any residual serum-containing media twice using DPBS. Adequate
mechanical dissociation is essential; scoring of the stromal matrix can assist the action of
trypsin.Note: OP9 stroma can be passaged extensively provided morphology remains stable.
Note: Once good quality cultures are established freeze aliquots of low passage cells at a
ratio of 1:3–1:4 per 10cm plate in 90% qualified-FBS/10% DMSO.10. Expand stocks of MS5 stroma.a. Make porcine gelatin (0.1% w/v porcine gelatin from powder in DPBS, autoclaved).
b. Add 5 mL porcine gelatin to 75 cm2 flasks and incubate at 37C for a minimum of 2 h prior to
seeding cells.
c. Make MS5-maintenance (MS5-M) media.
d. Thaw MS5 in 103 volume of MS5-M media, centrifuge at 300 g for 5min and seed pellet into
pre-gelatinized 75 cm2 flask in 12ml MS5-M media.
e. Monitor daily and split when 80% confluent (Figure 3A).
CRITICAL: Do not allow MS5 maintenance cultures to overgrow (Figure 3B).
f. On passaging, carefully remove media, wash with 5 mL DPBS.
g. Add 5 mL trypsin (0.05% in DPBS, 5 mM EDTA) and incubate at 37C for 5 min.
h. Quench trypsin with 5 mL MS5-M media and titurate until cells have visibly detached.
i. Transfer pellet to 15 mL conical tube, centrifuge at 300 g for 5min.
j. Split pellet 1:4–1:12 into a new gelatinized 75 cm2 flasks.
Note:Once good quality cultures are established freeze aliquots of low passage cells in 90%
qualified-FBS/10% DMSO.STAR Protocols 2, 100420, June 18, 2021 5
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OPEN ACCESS ProtocolKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD10-BV421 BD Cat# 562902; RRID: AB_2737879
CD11b-APC Biolegend Cat# 301310; RRID: AB_314162
CD14-PECy7 Biolegend Cat# 325618; RRID: AB_830691
CD19-PE Biolegend Cat# 302254; RRID: AB_2564142
CD19-APC Biolegend Cat# 302212; RRID: AB_314242
CD20-BV510 BD Cat# 563067; RRID: AB_2737985
CD31-APC Biolegend Cat# 303116; RRID: AB_1877151
CD33-BV786 BD Cat# 740974; RRID: AB_2740599
CD34-PECy7 Biolegend Cat# 343516; RRID: AB_1877251
CD43 FITC BD Cat# 555475; RRID: AB_395867
CD45-Alexa700 BD Cat# 560566; RRID: AB_1645452
CD45RA-FITC ThermoFisher Cat# MHCD45RA01; RRID: AB_10373858
CD45RA-BV711 Biolegend Cat# 304138; RRID: AB_2563815
CD127 (IL7R)-PE Biolegend Cat# 351304; RRID: AB_10720185
CD335-BV421 BD Cat# 564065; RRID: AB_2738572
IgM-BV510 BD Cat# 563113; RRID: AB_2738010
Human Fc Block BD Cat# 564220; RRID: AB_2869554
Chemicals, Peptides, and Recombinant Proteins
Human basic Fibroblast Growth
Factor (hbFGF)
Amsbio Cat# AMS-480-100; GenPept: P09038
Human Interleukin 3 (hIL-3) PeProTech Cat# 200-03; GenPept: P08700
Human FLT3 Ligand (hFLT3L) PeProTech Cat# 300-19; GenPept: P49771
Human Stem Cell Factor (hSCF) PeProTech Cat# 300-07; GenPept: P21583
Human Interleukin 7 (hIL7) PeProTech Cat# 200-07; GenPept: P13232
StemFit Basic04 Amsbio Cat# SFB-504
Matrigel Corning Cat# 354277
Y27632 (Rock Inhibitor) Cell guidance systems Cat# SM02-10; CAS: 146986-50-7
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich Cat# D2650; CAS: 67-68-5
Knock out replacement serum (KORS) Gibco Cat# 10828010
Gentle Cell Dissociation Reagent (GCDR) Stem Cell Technologies Cat# 07174
ReLeSR Stem Cell Technologies Cat# 05872
Qualified FBS Gibco Cat# 26140079
DMEM/F12 Gibco Cat# 21331046
aMEM powder Gibco Cat# 12000014
Sodium Bicarbonate Solution (7.5%) Sigma-Aldrich Cat# S8761; CAS: 144-55-8
Distilled Water (tissue culture grade) Gibco Cat# 15230188
DPBS, Ca2+/Mg2+ free Gibco Cat# 14190169
Monothioglycerol (MTG) Sigma-Aldrich Cat# M6145; CAS: 96-27-5
Pencillin/Streptomycin Gibco Cat# 15140122
Collagenase, Type IV, powder Gibco Cat# 17104019
EDTA 0.5M Sigma-Aldrich Cat# E7889; CAS: 139-33-3
Trypsin 2.5% Gibco Cat# 15090046; CAS: 9002-07-7
Bovine gelatin solution (Type B, 2%) Sigma-Aldrich Cat# G1393; CAS: 9000-70-8
Gelatin from porcine skin (Type A)powder Sigma-Aldrich Cat# G1890; CAS: 9000-70-8
7-Aminoactinomycin D (7-AAD) (viability) BD Cat# 559925; RRID: AB_2869266
Trypan Blue (0.4%) ThermoFisher Cat# 15250061; CAS: 72-57-1
Critical Commercial Assays
QuadroMACS Separator Miltenyi Biotec Cat# 130-090-976
MACS LS Columns Miltenyi Biotec Cat# 130-042-401
CD34 MicroBead Kit, human Miltenyi Biotec Cat# 130-046-702; RRID: AB_2848167
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Cell Lines
ShiPS-MIFF1 University of Sheffield https://hpscreg.eu/cell-line/UOSi001-A
ShiPS-MIFF3 (RRID:CVCL_1E70) University of Sheffield http://hpscreg.eu/cell-line/UOSi001-B
H1 WiCell http://hpscreg.eu/cell-line/WAe001-A
OP9 stroma ATCC Cat# CRL-2749; RRID: CVCL_4398
MS5 stroma DSMZ Cat# ACC 441; RRID: CVCL_2128
Software and Algorithms
Flowjo https://www.flowjo.com
Microscope Olympus, CKX53 N/A
Scale bar software ImageJ https://imagej.nih.gov/ij/
Other
10-cm Tissue Culture Dish Falcon Cat# 353003
6-Well Cell Culture Plate Corning Cat# 3516
Cell Culture Flask 75cm2 Corning Cat# 430641U
Disposable PES Filter Units (250 ml) Fisherbrand Cat# 15993297
Disposable PES Filter Units (500 ml) Fisherbrand Cat# 15913307
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OPEN ACCESSProtocolMATERIALS AND EQUIPMENTStemFit04 Final concentration Amount
StemFit Basic04 45ml
hbFGF (Stock: 100 ng/ml) 10ng/mL 4.5ml
Penicillin/Streptomycin (optional) 1% 450ml
Store at 4C for up to 1 week.
Y27632 (ROCK Inhibitor)
10003 stock Final concentration Amount
Y27832 powder 10 mM (10003) 2mg
Distilled Water (tissue culture grade) 624.4ml
Make working aliquots and store at 20C. Use 1:1000 (final concentration 10mM).
aMEM from Powder Final concentration Amount
aMEM Powder (10.38 mg) 13 1 vial (10.38g)
7.5% Sodium Bicarbonate (NaHCO3) (culture grade) 29.3ml
Distilled Water (tissue culture grade) 970ml
Total n/a 1L
Filter over a 0.22 mm membrane and store at 4C for up to 1 month.
Monothioglycerol (MTG)
10003 stock Final concentration Amount
MTG 100 mM 10ml
DPBS (Ca2+/Mg2+ free) 13 1150ml
Make fresh.
STAR Protocols 2, 100420, June 18, 2021 7
OP9-Differentiation media Final concentration Amount
aMEM from powder 13 445ml
Qualified FBS 10% 50ml
Monothioglycerol (MTG) 10003 (100mM) 100mM 500ml
Penicillin/Streptomycin 1% 5ml
Total n/a 500mL
Filter over a 0.22 mm membrane and store at 4C for up to 2 weeks.
OP9-Maintenance media Final concentration Amount
aMEM from powder 13 197.5ml
Qualified FBS 20% 50ml
Monothioglycerol (MTG) 10003 (100 mM) 100mM 250ml
Penicillin/Streptomycin 1% 2.5ml
Total n/a 250mL
Filter over a 0.22 mm membrane and store at 4C for up to 2 weeks.
MS5-Maintenance media Final concentration Amount
aMEM from powder 13 445ml
Qualified FBS 10% 50ml
Penicillin/Streptomycin 1% 5ml
Total n/a 500mL
Filter over a 0.22 mm membrane and store at 4C for up to 2 weeks.
Bovine gelatin Final concentration Amount
Bovine gelatin 2% (tissue-culture grade) 0.1% 25ml
DPBS (Ca2+/Mg2+ free) 475ml
Filter over a 0.22 mm membrane and store at 4C for up to 6 months.
Porcine gelatin Final concentration Amount
Porcine gelatin 0.1% w/v 0.5g
DPBS (Ca2+/Mg2+ free) 500ml
Autoclave and store at 4C for up to 6 months.
Collagenase IV
103 stock Final concentration Amount
Collagenase IV powder 10mg/mL 1g
DMEM/F12 100ml
Filter over a 0.22 mm membrane, aliquot and store at 20C for up to 6 months.
To make 13 working solution dilute 103 in DMEM/F12. Always make fresh.
Trypsin/EDTA Final concentration Amount
Trypsin (2.5%) 0.05% 1ml
EDTA 0.5M 5mM 500ml
DPBS (Ca2+/Mg2+ free) 48.5ml
Use fresh for OP9.
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MACS Buffer Final concentration Amount
DPBS (Ca2+/Mg2+ free) 490ml
Qualified FBS 2% 10ml
EDTA (0.5M) 2mM 2ml
Filter over a 0.22 mm membrane, store at 4C and use within 1 month.
Antibodies - FACS staining Day10 Dilution Conjugate Clone
CD31 1:100 APC WM59
CD33 1:40 BV786 WM53
CD34 1:200 PECy7 581
CD43 1:40 FITC 1G10
CD45 1:80 Alexa700 HI30
CD45RA 1:40 BV711 HI100
CD127 (IL7R) 1:20 PE A019D5
7-Aminoactinomycin D (7-AAD) 1:500
Antibodies - FACS staining Day 31 Dilution Panel Conjugate Clone
CD10 1:80 B BV421 HI10a
CD11b 1:80 Myeloid APC ICRF44
CD14 1:80 Myeloid PECy7 HCD14
CD19 1:40/1:80 B/Myeloid APC/PE HIB19
CD20 1:80 B BV510 2HF
CD33 1:40 B/Myeloid BV786 WM53
CD34 1:160 B PECy7 581
CD45 1:80 B/Myeloid Alexa700 HI30
CD45RA 1:40 B/Myeloid FITC MEM-56
CD127 (IL7R) 1:20 B PE A019D5
CD335 1:60 Myeloid BV421 9E2
IgM (option for CD20) 1:100 B (option) BV510 G20-127
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OPEN ACCESSProtocolDivide into two samples to stain for both mature myeloid markers and B cell progenitor markers (not
all markers shown in Figure 8).
7-Aminoactinomycin D (7-AAD) 1:500 B/MyeloidInstrument Laser wavelength Laser power PMTs and filter configurations
BD FACS AriaIII Violet 405nm 30 mW A: 780/60: B:710/50: C: 665/30: D: 610/20; E:
510/50; F: 450/40
Blue 488nm 20 mW A: 680/13; B: 525/50; C: 488/10
Yellow-Green 561nm 50 mW A: 780/60; B: 710/50; C: 670/14; D: 610/20; E: 582/15
Red 640nm 17mW A: 780/60; B: 730/45; C: 660/20
BD LSR Fortessa X20 UV 355nm 15 mW A: 525/50; B: 379/28
Violet 405nm 50 mW A: 780/60: B:710/50: C: 670/30: D: 610/20; E:
525/50; F: 450/50
Blue 488nm 60 mW A: 710/50; B: 530/30; C: 488/10
Yellow-Green 561nm 50 mW A: 780/60; B: 710/50; C: 670/30; D: 610/20; E: 586/15
Red 640nm 40 mW A: 780/60; B: 730/45; C: 670/30
STAR Protocols 2, 100420, June 18, 2021 9
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OPEN ACCESS ProtocolSTEP-BY-STEP METHOD DETAILS
Prepare hPSCs and overgrown plates of OP9 stroma
Timing: 8–12 days
Whole hPSC colonies are harvested and co-cultured on overgrown OP9 stroma for 10 days. During
this time differentiation is directed towards mesodermal and later hematopoietic-competent endo-
thelial progenitors. At day 10, CD34+ cells are harvested and co-cultured for a further 21 days on
MS5 stroma in media supplemented with lymphomyeloid cytokines.
Note: Whilst hPSCs can be readily differentiated into many other hematopoietic linages,
achieving B cell differentiation is more challenging. It remains unclear to us as to whether
this reflects to some unique aspect of B cell biology, or some as yet undefined aspect of
the protocol. When establishing this technique we therefore stress the importance of careful
validation of reagents and strict adherence to protocol.
1. Overgrow OP9 cultures.
a. On day 4 after seeding remove 5 mL of media from OP9 plates to be used for differentiation
and replace with 5 mL fresh, warm OP9-M media.
b. The ideal timing to add hPSCs to OP9 is day 8 after seeding, but this can be extended to 10–
12 days if stromal morphology remains robust. 5 mL off/on media changes should be per-
formed every 4 days.
2. Prepare hPSCs for harvest.
a. Passage hPSCs 3–5 days in advance of harvest for use on OP9 at such a density as to provide
large undifferentiated colonies.
b. Continue to feed with StemFit media daily or according to recommendation by manufacturer.Harvest hPSCs and seed onto overgrown plates of OP9 stroma
hPSCs are harvested, ideally as whole colonies or large clumps, washed and seeded onto overgrown
OP9 in OP9-differentiation (OP9-D) media. The schedule of feeding of these co-cultures is critical
and adhering to the timings stated here is highly recommended. During 10 days of co-culture, a se-
ries of characteristic morphological changes are observed as indicated in Figures 4A–4D.
3. Harvest hPSCs as whole colonies using collagenase.
a. Aim to harvest between 1.5-23106 hPSCs (1–3 wells of a 6 well plate) per 10 cm dish of OP9.10Note: In our experience the surface area of OP9 used rather than the number of hPSCs added
is the principal determinant of CD34+ cell yield.
b. Prepare fresh collagenase IV solution in DMEM/F12 basal media and warm to 37C.
c. Remove StemFit media and replace with 1 mL of warmed collagenase IV.
d. Incubate at 37C for 30–90 mins until colonies start to detach.
Note: Some manual agitation of the plate can assist during this time, but every effort should
be made to prevent break up of colonies.
e. Once themajority of colonies are detaching, use OP9-Dmedia to gently wash whole hPSC col-
onies/clumps from the well into a 50 mL conical tube using a serological pipette.
f. The colonies are washed 3 times in 10 mL OP9-D media by gravity alone.
CRITICAL: Do not pellet by centrifugation as this results in break-up of colony structure.g. Remove OP9-M media from overgrown OP9 plate and add 5 mL OP9-D mediaSTAR Protocols 2, 100420, June 18, 2021
Figure 4. Morphological changes during hPSC-OP9 coculture
(A) Morphology of overgrown OP9 stroma at 8 days post passage, ready to be seeded with hPSCs.
(B) Early hPSC (MIFF3) colony growing on OP9 stroma (day 2 of co-culture).
(C) hPSC (MIFF3) colony starting to differentiate on OP9 stroma (day 7 of co-culture).
(D) Differentiated hPSCs (MIFF3) at day 10 of OP9 stroma co-culture at time of harvest.
Microscope Olympus, CKX53. Scale bars were added using ImageJ software.
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OPEN ACCESSProtocolh. After the final wash, hPSC colonies are gently resuspended in 5 mL OP9-D media and trans-
ferred to the overgrown OP9 plate using a 10 mL serological pipette.
i. Ensure that colonies are evenly distributed across the available surface area by gentle agita-
tion.
4. Feed OP9-hPSC co-cultures.
a. Day 1: Gently swirl plate, remove all media and hPSC cell debris and gently replace with 20 mL
OP9-D media, taking care not to detach the stromal layer.
b. Day 4: Exchange 10 mL off/on OP9-D media.
c. Day 6: Exchange 10 mL off/on OP9-D media.
d. Day 8: Exchange 10 mL off/on OP9-D media.Harvest hPSC-derived CD34+ cells and seed onto MS5
5. Day 9: Prepare 6 well plates of MS5 stroma.
a. Pre-gelatinize (porcine gelatin 0.1%w/v) the required number of wells of a 6 well plate for a
minimum of 2 h prior to seeding MS5.
b. Harvest and count MS5 cells as per maintenance protocol above.
c. Seed up to 23105 MS5 cells per well of a 6 well plate in MS5-M media.
Note: At the time of seeding the MS5 are approaching confluency. We have not found it
necessary to mitotically inactivate MS5.
6. Day 10: Disassociate OP9-hPSC co-culture by collagenase and trypsin digest.
Note: By day 10 colony morphology should represent that shown in Figure 4D. Some degree
of background adiposity (<20%) of the OP9 stroma is to be expected by this time.
a. Prepare and warm fresh collagenase IV and trypsin according to description in Materials and




Protocolb. Remove all media from the OP9-hPSC plate to a 50 mL conical tube on ice.
Optional: If more than one plate is being harvested, pellet any non-adherent cells in the used
media by centrifugation at 300g for 5min and discard supernatant. The disassociated stroma
harvested in step 6k can be added to this pellet, thus collecting both adherent and non-
adherent cells present in the co-culture.
c. Add 7 mL warmed collagenase IV 1 mg/mL in DMEM/F12 and incubate at 37C for 25 min.
Gently swirl the collagenase to wash off residual serum-containing media.
CRITICAL: The use of collagenase is the only wash-step prior to adding trypsin. For thetrypsin not to be inhibited by residual FBS it is essential to remove all media carefully and
swirl the collagenase to wash residual serum from the tissue culture plate.d. Carefully remove and discard collagenase, avoiding losing cellular material or detaching the
stromal layer.
Note: Take care not to discard cellular debris after the collagenase wash. We do not collect
collagenase-containing media to reduce exposure of cells to enzyme.
e. Add 7 mL freshly prepared 0.05% trypsin/5 mM EDTA.
f. In order to prevent the stromal layer detaching en-bloc into an indigestible ball, score the
stromal matrix orthogonally into approximately 1 cm2 sections using a 1 mL micropipette tip.
g. Incubate at 37C.
h. Agitate the plate intermittently during incubation to facilitate trypsin exposure to the under-
side of the stromal layer.
i. After 3–7 min use a 10 mL serological pipette to titurate the stroma, before quenching trypsin
with 7 mL OP9-D media.
j. Further titurate with a 1 mL pipette to break up clumps.
k. Collect the cellular material into the 50 mL conical tube used in step 6b though a 40–70 mm
nylon filter (pre-wetted with MACS buffer).
l. Wash the plate with 5 mL MACS buffer and add to 50 mL conical tube through the 40–70 mm
nylon filter.
m. Wash the filter twice with 1 mL MACS buffer.
n. Discard the filter and pellet cells by centrifugation at 300 g for 5min.
7. Magnetic separation of CD34+ cells.
a. Resuspend cell pellet in 300 mL chilled MACS buffer.
b. Incubate with 100 mL Fc receptor block for 5 min on ice.
c. Add 100 mL anti-CD34 MACS beads and incubate at 4C for 30 min on a rotator.
d. Load Miltenyi LS MACS column into magnet holder, insert 30–50 mm sterile filter and place
over a collection tube/reservoir.Optional: Flow through can be retained and analyzed by flow cytometry to estimate the rela-
tive CD34+ enrichment (Figure 5).
e. Prime column with 3 mL of chilled MACS buffer.
f. After incubation wash cells with 5 mL chilled MACS buffer, centrifuge at 300 g 4C for 5 min.
g. Resuspend the cell pellet in 500 mL chilled MACS buffer and add to the MACS LS column
through the cell strainer.
h. Once the column stops dripping, wash with 3 mL chilled MACS buffer.
i. When the column stops dripping, repeat 3 mL wash to a total of 3 washes.
j. Remove the column from the magnet, discard the strainer and extract the cells by applying
5 mL chilled MACS buffer and rapid plunging the enriched cells into a fresh 15 mL conical
tube. Repeat once more with 3 mL buffer to increase the yield of CD34+ cells.
k. Centrifuge enriched cells at 300 g for 5 min.STAR Protocols 2, 100420, June 18, 2021
Figure 5. MACS enrichment of CD34+ cells
Cells were harvested after OP9 culture on day 10 and enriched for hematopoietic progenitors using CD34 MACS
beads. Cells in the CD34 positive and CD34 negative fraction were then stained for CD34 and analyzed by flow
cytometry. Cells were gated for singlets, viability, and scatter profile. Histogram shows cells that express CD34 in the
negative (gray) and positive (red) fraction respectively. After successful enrichment over 95% of the enriched cells are
CD34+ and fewer than 5% CD34+ cells can be recovered from the CD34 depleted fraction.
ll
OPEN ACCESSProtocoll. Resuspend the CD34-enriched pellet in 0.5 mL OP9-D media and count cells using a hemocy-
tometer counterstained with Trypan blue. CD34+ cells are small, phase-bright or phase-
neutral. Exclude dead (blue) or very large, phase-bright stromal cells from the cell count esti-
mation.
CRITICAL: The production of CD34+CD43+CD45+ hematopoietic progenitors by day 10of co-culture is a pre-requisite for later B cell potential and therefore careful assessment of
day 10 intermediate progenitors is essential when establishing this protocol. In our expe-
rience the presence of a small population of CD34+CD45RA+IL7R+ progenitors at day 10 is
associated with robust B cell differentiation during subsequent MS5 co-culture (Figure 6).
The quality of OP9 stroma and batch of the serum used are the most critical aspects of this
part of the protocol.Optional: When establishing this protocol, we recommend staining for the presence of he-
matopoietic progenitors at day 10.
Note: After this first part of the protocol harvested cells can be further cultured to generate
myeloid cells as described in (Choi et al., 2011).Flow cytometry of hPSC-derived CD34+ cells
8. Take an aliquot of the CD34-enriched fraction for staining. There is no need to addmore Fc block-
ing as this was done in step 7b.
9. Stain according to protocol below (step 15). Suggested antibodies are listed in Materials and
Equipment section and typical results shown in Figure 6.
Note: Trypsin/collagenase exposure may destroy surface antigens. See troubleshooting
section.STAR Protocols 2, 100420, June 18, 2021 13
Figure 6. Flow cytometry analysis from day 10 of co-culture
Cells were harvested after OP9 culture on day 10, enriched for CD34 and stained for surface markers. Cells were gated
for singlets, viability, and scatter profile (top row) and then for CD43 expression (middle right). Of the 7AAD-CD43+
emerging hematopoietic cells, a small fraction (about 1.6% in this experiment) co-express IL7R and CD45RA (middle
center). In the histograms, expression of the hematopoietic-endothelial markers CD31 and CD34 and the pan-
hematopoietic (CD45) and myeloid (CD33) markers within the 7AAD-CD43+ fraction are shown. We find that about
75% of the enriched cells express the early hematopoietic marker CD43. Percentages presented are of total
7AAD-CD43+ cells.
ll
OPEN ACCESS ProtocolLympho-myeloid differentiation of hPSC-derived CD34 cells by MS5 co-culture
10. Prepare sufficient OP9-D media with 23 final cytokine concentrations for the number of CD34
cells harvested.14a. Final cytokine concentration: hIL3 10 ng/mL, hIL7 20 ng/mL, hFlt3L 50 ng/mL, hSCF 50 ng/
mL.
b. Remove MS5-M media from 6 well plate.
c. Add 1 mL per well of 23 cytokine containing OP9-D media to MS5 on a 6 well plate.11. Dilute CD34+ cell pellet such as to add 12.5–503103 CD34-enriched cells per well of MS5 on
a 6 well plate in 1 mL OP9-D media. Final volume is 2 mL/well with 13 final cytokine concentra-
tion.
12. On day 17 of culture (day 7 onMS5) add 2mLOP9-Dmedia containing 13 cytokines: hIL7 20 ng/
mL, hFlt3L 50 ng/mL, hSCF 50 ng/mL (final concentration). Final volume is 4 mL/well with 13
final cytokine concentration (excluding IL-3).
13. On day 24 of culture (day 14 on MS5) carefully remove up to 2 mL (accounting for evaporation –
i.e., leaving 2 mL residual media) of media and replace with fresh OP9-D media supplemented
with 13 cytokines: hIL7 20 ng/mL, hFlt3L 50 ng/mL, hSCF 50 ng/mL (final concentration). Final
volume is 4 mL/well with 13 final cytokine concentration (excluding IL-3).STAR Protocols 2, 100420, June 18, 2021
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OPEN ACCESSProtocolNote: At this stage non-adherent hematopoietic cells should be clearly visible in the center of
the well; it is therefore advisable to takemedia from the edge of the well. If significant numbers
of non-adherent cells are removed, centrifuge the media at 300g for 5 min and reseed the pel-
let into the initial well in the fresh OP9-D media supplemented with cytokines as above.
Note: Small numbers of CD34+CD19+ proB cells are usually detectable by day 24 of culture
(after 14 days on MS5)
14. On day 31 (27–33) harvest cells for analysis. Small hematopoietic cells can now be seen floating
in the media as per Figure 7.a. Use a cell scraper to mechanically detach stroma and titurate with a 1 mL micropipette into a
single cell suspension.
b. Centrifuge cells at 300 g for 5min and discard supernatant.
c. Resuspend cell pellet in 50 mL Fc receptor block and incubate for 10 min at 4C, aiming for a
total 100 mL final staining volume. This may need to be increased if large numbers of cells are
stained.
d. Stain for surface markers according to step 15. Suggested antibodies are listed in the Mate-
rials and Equipment section.
e. Analyze or flow sort cells for further analysis.
Note: By day 31 the MS5 stroma usually detaches easily and enzymatic treatment with colla-
genase is generally unnecessary and can affect the detection of some antigens by flow
cytometry.
Note: By day 31 fewer primitive CD34+ progenitor and proB cells are present. If specific
lymphoid progenitor populations are required harvesting earlier may be an advantage.Flow cytometric analysis (at day 10 to 31 of culture)
15. Cells are harvested at day 10 to 31 (from day 24–31 for B cells) of culture and stained with surface
markers for analysis or sorting on a flow cytometer.a. Make antibody staining cocktail with 23 concentrated antibodies in MACS buffer.
b. Include unstained cells and fluorescence minus one (FMO) controls for all colors. A stroma
only control is also recommended as the stroma may give high background.
c. Mix equal volume of 23 staining cocktail and Fc receptor blocked cells.
d. Stain in the dark on a shaker for 40 min at 4C.
e. Wash with 1 mL of MACS buffer.
f. Centrifuge at 300 g for 5 min.
g. Resuspend in MACS buffer containing 13 viability dye.
h. Set up the flow cytometry with single stained beads and cells stained with only viability
marker.
i. Suggested antibody cocktails are listed in Materials and Equipment section and expected
results can be seen in Figure 6 (day 10) and Figure 8 (day 31).
Note: We recommend that you titrate the antibodies to find optimal concentration for your
staining.
Note: Staining volume needs to be adjusted to number of cells.
Note: MS5 stroma may give a high background staining; we suggest growing and staining
MS5 stroma with no hematopoietic cells as a control. We use anti-human CD45 to specifically
gate on the hPSC-derived blood cells and exclude stroma that are of mouse origin.STAR Protocols 2, 100420, June 18, 2021 15
Figure 7. Morphology after three weeks of MS5 co-culture
MS5 co-culture with hematopoietic cells one day before harvest. Small, phase bright hematopoietic cells are seen
floating in the media. The MS5 stroma can be seen in the background.




ProtocolNote: Our staining suggestion was done on a BD Fortessa X20 or BD Aria III according to
configuration in Materials and Equipment section. For cell sorting we recommend using
100mm nozzle to minimize mechanical stress on the cells.Expected outcomes
At day 10 of the protocol hematopoietic progenitors can be harvested, identifiable by expression
of the early hematopoietic marker CD43 and the later pan-hematopoietic marker CD45 (Carpenter
et al., 2011; Vodyanik et al., 2005). In our hands, about 70%–80% of the CD34-enriched
fraction express CD43 (Vodyanik et al., 2006) and of these approximately 40% also express
CD45. A small fraction of cells (usually R0.5% of CD43+) express the lymphoid IL7R surface marker
(Figure 6).
B cells emerge upon further co-culture on MS5; in our experience CD34+CD19+ proB cells can be
detected after about 2 weeks of MS-5 culture, but kinetics may differ between different hPSC lines.
After three weeks of MS5 culture (31 days total) more mature CD19+ preB cells emerge; these have
lost expression of CD34 and homogenously express CD10 and CD20 (Figure 8). Surface IgM expres-
sion is not detected (data not shown).LIMITATIONS
The quality and provenance of the stroma used and its maintenance in appropriate conditions is crit-
ical in the specification of lymphoid-permissive hematopoietic progenitors by day 10 of culture and
subsequent B cell output.
Differentiation biases in hPSC lines are likely to affect their ability to differentiate into hematopoietic
progenitors and the B lineage. New hPSC lines should be evaluated alongside an hPSC line with
known B lineage potential as a positive control.
Surface IgM positive naı̈ve B cells are not generated by day 31 of culture although IgM+ B cells have
though been reported after extended culture (French et al., 2015).
Hematopoietic progenitors derived from hPSCs have not been demonstrated to robustly engraft in
immunosuppressed mice, thus limiting assessment of in vivo self-renewal capacity (Slukvin, 2013).
The protocol uses xenogenic stroma and serum, which makes it unsuitable as a future Good
Manufacturing Practice (GMP) protocol.STAR Protocols 2, 100420, June 18, 2021
Figure 8. Flow cytometry analysis from approximately day 31 of co-culture
Cells were harvested after 3 weeks of MS5 co-culture and stained for surface markers.
(A) Cells were gated for singlets and scatter and then for viability (7AAD) and CD45 expression as indicated in the
figure (top panel). Expression of CD19 and CD34 is shown within the 7AAD-CD45+ fraction (second panel, left). The
CD19 positive fraction is further gated for expression of CD10 and CD20 (right). Counting beads were used in this
experiment and can be seen in the scatter plot in the top middle panel.
(B) Cells were gated for singlets and scatter (as in Figure 8A, plots not shown). Contour plot of viability (7AAD) and
CD45 expression as shown in the figure (left). Further gating on 7AAD-CD45+ cells for B lymphoid (CD19) and, within




Poor hPSC morphology or high cell death (before you begin - step 6).Potential solution
hPSC cultures are prone to spontaneous differentiation or cell death. EnsureMatrigel is used accord-
ing to manufacturer’s instructions, specifically: use the dilution factor supplied with each lot, ensure
that it is handled on ice until ready for use and that coated plates are not used beyond 7 days after
aliquot thawing.
Different cell lines grow variably in commonly usedmedia. We have found that H1 hES or MIFF3 hIPS
cell grow robustly in mTeSR1 or StemFit (Basic04). Cell line variability can be controlled by growing a
commonly used cell line (such as H1 hES orMIFF3 hIPS) in parallel. Regular media changes are essen-
tial as hbFGF is thermolabile and ongoing signaling is required for maintenance of the pluripotent
stem cell state.STAR Protocols 2, 100420, June 18, 2021 17
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OPEN ACCESS ProtocolhPSC colonies should not be allowed to overgrow and passaging frequency will need to be opti-
mized depending on culture conditions to achieve morphology seen in Figure 1A. Smaller areas
of differentiation are often selected against during passage, but if problematic can be removed
either manually or with ReLeSr reagent during passage.Problem 2
Poor OP9 morphology (before you begin - step 9).Potential solution
Maintaining stable OP9 cultures with a morphological profile similar to that shown in Figure 2 is
essential for generating hematopoietic progenitors. The OP9 we use for hPSC differentiation are
handled differently to those we use for standard hematopoietic differentiation assays and stored
as separate sub-lines. We therefore recommend passaging new OP9s using the conditions
described above until stable morphology is achieved before freezing down working stocks. Specific
attention should be paid to: i) choice of plastic of cell culture dishes; ii) adequate gelatinization of cell
culture dishes; iii) use of qualified, batch-tested serum; iv) use of basal aMEMmediamade from pow-
der; v) seeding density; vi) passaging completely using fresh aliquots of trypsin at 80% confluence.Problem 3
There are few/no CD34+CD43+ hematopoietic cells at day 10 of OP9 co-culture (step 8).Potential solution
The problem is most likely the quality of the OP9 stroma. Ensure you are using the correct type of
tissue culture plastic and that this is well gelatinized. The stroma is sensitive to inter-batch variation
in qualified FBS and the basal aMEMmedia should bemade from powder. Do not allowOP9 to over-
grow during maintenance phase and ensure complete trypsinization at passage. Higher passage
OP9 can become exhausted. Good quality OP9 should appear as in Figures 2A and 2B in the main-
tenance phase and Figure 4A before start of the co-culture with hPSCs.
Another reason can be variability in the differentiation potential of the hPSC line used. Include a con-
trol cell line that is known to produce blood cells such as H1 hES, MIFF1 or MIFF3 iPS cell lines.
Ensure hPSC cultures are stable and free from significant baseline differentiation.Problem 4
No B cells (CD19+) at day 31 of co-culture (step 14).Potential solution
Most likely there is a problem with either the OP9 stroma, MS5 stroma or the qualified serum. If you
see expression of CD43 and CD45 and a small population of IL7R positive cells at day 10 then the
OP9 stroma is probably satisfactory. We then suggest you test your MS5 culture system using
cord blood-derived progenitor cells in parallel to confirm B lineage output. Lineage negative
CD34+CD38-CD45RA+CD10+ cord blood cells should, for instance, give robust B cell output in
bulk MS5 co-culture (Doulatov et al., 2010).
There could also be a general differentiation issue with the hPSC cell line used. We therefore recom-
mend establishing the protocol with a well maintained hPSC line with known B lineage potential such
as H1 hES, or MIFF1 / MIFF3 iPS cell lines.Problem 5
Flow cytometric analysis shows lack of expression of a specific surface antigen (step 9 and 15).18 STAR Protocols 2, 100420, June 18, 2021
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OPEN ACCESSProtocolPotential solution
Some surface antigens are sensitive to collagenase/trypsin treatment. To test if this is the reason,
cells known to express the surface antigen (e.g., control cord blood) can be stained with and without
prior exposure to collagenase and/or trypsin treatment and analyzed. If the surface antigen is sen-
sitive to the enzymatic degradation, we suggest reducing exposure to the enzyme or trying a
different clone of antibody, if available.
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact, Simon Richardson (ser32@cam.ac.uk).
Materials availability
This study did not generate new unique reagents.
Data and code availability
No new code was established in this study.
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